Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

A roundup of some of the North American equities making moves in both directions today

On the rise

Aimia Inc. (AIM-T) surged over 13 per cent on Wednesday after announcing before the bell it has acquired a 10-per-cent stake in Chinese outdoor advertising firm Clear Media Ltd. for $75-million.

The move comes as the company works to transform itself from a loyalty rewards company into an investment holding firm.

Story continues below advertisement

Aimia says it has acquired 58.8 million common shares in Clear Media, including 19.6 million previously held by clients of Mittleman Investment Management which is also Aimia’s largest shareholder.

It says the investment was made in anticipation of a pending deal by Clear Media’s controlling shareholder, Clear Channel Outdoor, to sell its 50.9-per-cent stake to Ever Harmonic Global Ltd.

The acquisition was announced as Aimia reported a first-quarter loss of $9.6-million or 14 cents per share compared with a profit of $1.05-billion or $6.85 per share a year ago when its results were boosted by the sale of its Aeroplan business to Air Canada.

Uber Technologies Inc. (UBER-N) closed up 2.1 per cent in the wake of announcing an offering of US$750-million in senior notes due 2025.

It intends to use the net proceeds for working capital and other general corporate purposes, “which may include potential acquisitions and strategic transactions.”

On Tuesday, reports surfaced that Uber is in advanced talks to buy online food delivery company GrubHub Inc. (GRUB-N) in an all-stock deal, according to a person familiar with the matter.

A deal could make Uber more competitive with market leader DoorDash.

Story continues below advertisement

The coronavirus pandemic has upended Uber’s core business of paying freelance drivers to shuttle people from place to place. A merger of its loss-making Uber Eats restaurant delivery service with GrubHub shows how the Silicon Valley disruptor is scrambling to pivot in what promises to be a long period of business interruption by doubling down on its fastest growing business.

Shares of Grubhub were down 3.7 per cent on Wednesday.

On the decline

Canadian Natural Resources Ltd. (CNQ-T), Cenovus Energy Inc. (CVE-T), Suncor Energy Inc. (SU-T), and Imperial Oil Ltd. (IMO-T) were all trading lower after being excluded by the Norwegian central bank from its $1-trillion wealth fund, the world’s largest, for producing too much greenhouse gas emissions, its first use of carbon emissions as a criterion to blacklist firms.

In a statement, Norges Bank said the firms were excluded from the fund due to “unacceptable greenhouse gas emissions."

The decision was based on recommendations from the Council on Ethics, the fund’s ethics watchdog, because of the companies’ carbon emissions from production of oil to oil sands, the central bank said.

Royal Caribbean Cruises Ltd. (RCL-N) dipped 5 per cent after it launched a new US$3.3--billion bond offering on Wednesday and said it would use 28 of its ships as collateral, as it looks to stay afloat after the COVID-19 pandemic upended the industry.

Story continues below advertisement

The company, which was forced to suspend its cruises globally and cut about 26 per cent of its U.S. workforce, said it would use the proceeds from the private note offering to repay a US$2.35-billion 364-day term loan agreement with Morgan Stanley.

Earlier in May, rival Norwegian Cruise Line Holdings Ltd. (NCLH-N) had raised over US$2.2-billion through debt and equity offerings, giving it much needed funds to survive for at least the next 18 months. The company used two of its ships and two private islands as collateral for the debt offering.

It was not immediately clear which ships Royal Caribbean pledged for the offering. It had vessels with a net book value of about US$22.7-billion as of Dec. 31, including the world’s largest cruise ship - Symphony of the Seas.

Shares of Norwegian and rival Carnival Corp. (CCL-N) were down 7.2 per cent.

Tesla Inc. (TSLA-Q) lost 2.3 per cent after Alameda County officials said it can take additional steps ahead of a potential reopening of its California assembly plant as soon as Monday after Chief Executive Elon Musk had vowed to defy authorities and won the backing of President Donald Trump.

In a tweet posted around midnight, Alameda said that following talks with Tesla it agreed that the electric carmaker can take steps “in preparation for possible reopening as soon as next week.”

Story continues below advertisement

Tesla did not immediately comment Wednesday but around the same time the county issued its statement, Musk tweeted: “Life should be lived.”

Tesla’s sole U.S. electric vehicle assembly plant is in Fremont, California, which is in Alameda County.

The county said it would work with police in Fremont “to verify Tesla is adhering to physical distancing and that agreed upon health and safety measures are in place for the safety of their workers as they prepare for full production.”

On Monday, Musk said production was resuming in Fremont, defying an order to stay closed and saying if anyone had to be arrested, it should be him.

On Tuesday, Musk won Trump’s backing. “California should let Tesla & @elonmusk open the plant, NOW. It can be done Fast & Safely!” Trump wrote on Twitter.

See also: Trump wants California to let Tesla reopen assembly plant

Story continues below advertisement

Gilead Sciences Inc. (GILD-Q) slipped 1.2 per cent after it said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.

The pacts allow the companies - Jubilant Life Sciences Ltd., Cipla Ltd., Hetero Labs Ltd, Mylan NV (MYL-Q) and Ferozsons Laboratories Ltd.- to make and sell the drug in 127 countries.

The countries consist of nearly all low-income and lower-middle income ones, as well as several that are upper-middle- and high-income, the drugmaker said. Afghanistan, India, North Korea, Pakistan and South Africa are among the countries.

The licensees will also set their own prices for the generic product they produce, Gilead said.

Shares of Mylan were down 4.2 per cent.

The U.S. Food and Drug Administration declined to review an experimental multiple myeloma therapy from Bristol Myers Squibb Co. (BMY-N) and bluebird bio Inc. (BLUE-Q) as it sought more details, the companies said on Wednesday.

Story continues below advertisement

Shares of bluebird bio fell 1.8 per cent, while those of Bristol Myers dipped 0.1 per cent.

The FDA in its so-called refusal to file letter asked for further details on the chemistry and manufacturing of the therapy, named ide-cel, but did not request any additional clinical data, the companies said.

Ide-cel is one of the experimental therapies that Bristol Myers gained through its US$74-billion acquisition of Celgene Corp and its approval is linked to a higher payout to Celgene investors.

As part of the deal, Celgene investors are entitled to receive a contingent value right (CVR) payment of US$9 a share if three treatments achieve timely approvals.

The FDA last week extended its review for liso-cel, another treatment that is part of the CVR payout.

Walt Disney Co. (DIS-N) slipped 1.6 per cent after filing for US$11-billion in notes with varying terms due between 2026 and 2060.

See also: Shanghai Disneyland reopens with anti-virus controls

With files from staff and wires

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies